SD5
5-[2,6-di(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine
| Created: | 2011-06-14 |
| Last modified: | 2011-06-14 |
Find Related PDB Entry |
|---|
Find related ligands:Help |
|---|
Chemical Details | |
|---|---|
| Formal Charge | 0 |
| Atom Count | 50 |
| Chiral Atom Count | 0 |
| Bond Count | 53 |
| Aromatic Bond Count | 12 |
Chemical Component Summary | |
|---|---|
| Name | 5-[2,6-di(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine |
| Systematic Name (OpenEye OEToolkits) | 5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine |
| Formula | C18 H21 F3 N6 O2 |
| Molecular Weight | 410.394 |
| Type | NON-POLYMER |
Chemical Descriptors | |||
|---|---|---|---|
| Type | Program | Version | Descriptor |
| SMILES | ACDLabs | 12.01 | FC(F)(F)c1cc(ncc1c3nc(nc(N2CCOCC2)c3)N4CCOCC4)N |
| SMILES | CACTVS | 3.370 | Nc1cc(c(cn1)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F |
| SMILES | OpenEye OEToolkits | 1.7.2 | c1c(c(cnc1N)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F |
| Canonical SMILES | CACTVS | 3.370 | Nc1cc(c(cn1)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F |
| Canonical SMILES | OpenEye OEToolkits | 1.7.2 | c1c(c(cnc1N)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F |
| InChI | InChI | 1.03 | InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23) |
| InChIKey | InChI | 1.03 | CWHUFRVAEUJCEF-UHFFFAOYSA-N |
Drug Info: DrugBank
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
| DrugBank ID | DB11666 |
|---|---|
| Name | Buparlisib |
| Description | Buparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, Lung Cancer, Solid Tumors, and Breast Cancer, among others. |
| Synonyms |
|
| Categories |
|
| CAS number | 944396-07-0 |
Related Resource References
| Resource Name | Reference |
|---|---|
| Pharos | CHEMBL2017974 |
| PubChem | 16654980 |
| ChEMBL | CHEMBL2017974 |
| ChEBI | CHEBI:71954 |














